Log in

NASDAQ:TMDXTransMedics Group Stock Price, Forecast & News

$13.21
-0.62 (-4.48 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.15
Now: $13.21
$13.95
50-Day Range
$13.83
MA: $16.10
$18.26
52-Week Range
$10.10
Now: $13.21
$30.17
Volume351,837 shs
Average Volume185,923 shs
Market Capitalization$282.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
CUSIPN/A
CIKN/A
Phone978-552-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.60 million
Book Value$2.19 per share

Profitability

Net Income$-33,550,000.00
Net Margins-134.19%

Miscellaneous

EmployeesN/A
Market Cap$282.17 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has decreased by 3.0% and is now trading at $13.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.02. The business earned $7.53 million during the quarter, compared to analyst estimates of $7.49 million. TransMedics Group had a negative net margin of 134.19% and a negative return on equity of 60.19%. View TransMedics Group's earnings history.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.4-7.5 million, compared to the consensus revenue estimate of $6.87 million.

What price target have analysts set for TMDX?

4 equities research analysts have issued 12 month target prices for TransMedics Group's shares. Their forecasts range from $16.00 to $28.00. On average, they expect TransMedics Group's share price to reach $22.00 in the next year. This suggests a possible upside of 66.5% from the stock's current price. View analysts' price targets for TransMedics Group.

Has TransMedics Group been receiving favorable news coverage?

Media stories about TMDX stock have trended negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransMedics Group earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutTransMedics Group.

Are investors shorting TransMedics Group?

TransMedics Group saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,310,000 shares, a decrease of 5.8% from the April 15th total of 1,390,000 shares. Based on an average trading volume of 136,000 shares, the days-to-cover ratio is currently 9.6 days. Approximately 8.3% of the company's shares are short sold. View TransMedics Group's Current Options Chain.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AT&T (T), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Beyond Meat (BYND), Walt Disney (DIS) and Etsy (ETSY).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.06%), Federated Hermes Inc. (2.28%), Zimmer Partners LP (2.20%), Emerald Advisers LLC (2.12%), Emerald Mutual Fund Advisers Trust (1.99%) and Massachusetts Financial Services Co. MA (1.21%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr, John F Carey, Stephen Gordon and Tamer I Khayal. View institutional ownership trends for TransMedics Group.

Which institutional investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Morgan Stanley, Roubaix Capital LLC, Zimmer Partners LP, UBS Group AG, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold TransMedics Group company stock in the last year include John F Carey, Stephen Gordon, and Tamer I Khayal. View insider buying and selling activity for TransMedics Group.

Which institutional investors are buying TransMedics Group stock?

TMDX stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Taylor Wealth Management Partners, State Street Corp, Bullseye Asset Management LLC, Geode Capital Management LLC, AXA, and Bank of New York Mellon Corp. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr. View insider buying and selling activity for TransMedics Group.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $13.21.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $282.17 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.